JP2014515039A5 - - Google Patents

Download PDF

Info

Publication number
JP2014515039A5
JP2014515039A5 JP2014510928A JP2014510928A JP2014515039A5 JP 2014515039 A5 JP2014515039 A5 JP 2014515039A5 JP 2014510928 A JP2014510928 A JP 2014510928A JP 2014510928 A JP2014510928 A JP 2014510928A JP 2014515039 A5 JP2014515039 A5 JP 2014515039A5
Authority
JP
Japan
Prior art keywords
polylactide
oligo
peg
polypeptide
chains
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014510928A
Other languages
English (en)
Japanese (ja)
Other versions
JP6215194B2 (ja
JP2014515039A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2012/052445 external-priority patent/WO2012156918A1/en
Publication of JP2014515039A publication Critical patent/JP2014515039A/ja
Publication of JP2014515039A5 publication Critical patent/JP2014515039A5/ja
Application granted granted Critical
Publication of JP6215194B2 publication Critical patent/JP6215194B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014510928A 2011-05-16 2012-05-16 生体直交型薬物活性化 Active JP6215194B2 (ja)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
EP11166241 2011-05-16
EP11166241.7 2011-05-16
EP11166942 2011-05-20
EP11166942.0 2011-05-20
US201161515458P 2011-08-05 2011-08-05
US201161515432P 2011-08-05 2011-08-05
US61/515,432 2011-08-05
EP11176741.4 2011-08-05
EP11176741 2011-08-05
US61/515,458 2011-08-05
EP11176736 2011-08-05
EP11176736.4 2011-08-05
EP11192577.2 2011-12-08
EP11192577 2011-12-08
EP11192572.3 2011-12-08
EP11192572 2011-12-08
PCT/IB2012/052445 WO2012156918A1 (en) 2011-05-16 2012-05-16 Bio-orthogonal drug activation

Publications (3)

Publication Number Publication Date
JP2014515039A JP2014515039A (ja) 2014-06-26
JP2014515039A5 true JP2014515039A5 (enExample) 2017-03-02
JP6215194B2 JP6215194B2 (ja) 2017-10-18

Family

ID=47176369

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2014510929A Active JP5993940B2 (ja) 2011-05-16 2012-05-16 生体直交型薬物活性化
JP2014510930A Active JP6482273B2 (ja) 2011-05-16 2012-05-16 生体直交型薬物活性化
JP2014510928A Active JP6215194B2 (ja) 2011-05-16 2012-05-16 生体直交型薬物活性化
JP2016161617A Ceased JP2017014262A (ja) 2011-05-16 2016-08-22 生体直交型薬物活性化
JP2018000737A Active JP6608467B2 (ja) 2011-05-16 2018-01-05 生体直交型薬物活性化

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2014510929A Active JP5993940B2 (ja) 2011-05-16 2012-05-16 生体直交型薬物活性化
JP2014510930A Active JP6482273B2 (ja) 2011-05-16 2012-05-16 生体直交型薬物活性化

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016161617A Ceased JP2017014262A (ja) 2011-05-16 2016-08-22 生体直交型薬物活性化
JP2018000737A Active JP6608467B2 (ja) 2011-05-16 2018-01-05 生体直交型薬物活性化

Country Status (9)

Country Link
US (8) US9421274B2 (enExample)
EP (4) EP2709666B1 (enExample)
JP (5) JP5993940B2 (enExample)
CN (4) CN103889459B (enExample)
AU (3) AU2012257418B2 (enExample)
CA (3) CA2836365C (enExample)
DK (1) DK2709667T3 (enExample)
ES (1) ES2920373T3 (enExample)
WO (3) WO2012156918A1 (enExample)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2709666B1 (en) * 2011-05-16 2021-07-14 Koninklijke Philips N.V. Bio-orthogonal drug activation
US9701998B2 (en) 2012-12-14 2017-07-11 10X Genomics, Inc. Methods and systems for processing polynucleotides
CN114891871A (zh) 2012-08-14 2022-08-12 10X基因组学有限公司 微胶囊组合物及方法
US10323279B2 (en) 2012-08-14 2019-06-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10584381B2 (en) 2012-08-14 2020-03-10 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11591637B2 (en) 2012-08-14 2023-02-28 10X Genomics, Inc. Compositions and methods for sample processing
US10752949B2 (en) 2012-08-14 2020-08-25 10X Genomics, Inc. Methods and systems for processing polynucleotides
WO2014065860A1 (en) * 2012-10-24 2014-05-01 The General Hospital Corporation Functionalized 1,2,4,5-tetrazine compounds for use in bioorthogonal coupling reactions
WO2014081300A1 (en) * 2012-11-22 2014-05-30 Tagworks Pharmaceuticals B.V. Channel protein activatable liposomes
WO2014081299A1 (en) * 2012-11-22 2014-05-30 Tagworks Pharmaceuticals B.V. Activatable liposomes
US10927139B2 (en) 2012-11-22 2021-02-23 Tagworks Pharmaceuticals B.V. Chemically cleavable group
US20150297741A1 (en) * 2012-11-22 2015-10-22 Tagworks Pharmaceuticals B.V. Bio-orthogonal drug activation
WO2014133620A2 (en) * 2012-12-07 2014-09-04 University Of Washington Through Its Center For Commercialization Thermally-activated self-immolative materials
US10533221B2 (en) 2012-12-14 2020-01-14 10X Genomics, Inc. Methods and systems for processing polynucleotides
KR20230003659A (ko) 2013-02-08 2023-01-06 10엑스 제노믹스, 인크. 폴리뉴클레오티드 바코드 생성
DK3611180T3 (da) 2013-03-15 2022-02-28 Biomolecular Holdings Llc Hybrid immunoglobulin indeholdende ikke-peptidyl-binding
EP3964237B1 (en) 2013-03-15 2026-02-18 Regeneron Pharmaceuticals, Inc. Biologically active molecules, conjugates thereof, and therapeutic uses
US20150087043A1 (en) * 2013-04-11 2015-03-26 Coferon, Inc Monomers capable of multimerizing in an aqueous solution that employ bioorthogonal chemistries, and methods of using same
EP3010486B1 (en) 2013-06-19 2023-11-22 The Regents of The University of California Chemical structures for localized delivery of therapeutic agents
AU2014311361B2 (en) 2013-08-26 2018-11-29 Regeneron Pharmaceuticals, Inc. Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses
KR20250051130A (ko) 2013-09-25 2025-04-16 싸이톰스 테라퓨틱스, 인크. 매트릭스 메탈로프로테이나제 기질 및 다른 절단성 모이어티 및 이의 사용 방법
EP3628328B1 (en) * 2014-01-31 2022-09-14 Cytomx Therapeutics Inc. Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
EP4169944A1 (en) 2014-03-14 2023-04-26 Biomolecular Holdings LLC Process for preparing hybrid immunoglobulin containing non-peptidyl linkage
AU2015229014B2 (en) 2014-03-14 2019-07-25 The Regents Of The University Of California TCO conjugates and methods for delivery of therapeutic agents
JP6787789B2 (ja) * 2014-04-04 2020-11-18 プレジデント アンド フェローズ オブ ハーバード カレッジ 詰め替え可能な薬物送達デバイスおよびその使用方法
US12312640B2 (en) 2014-06-26 2025-05-27 10X Genomics, Inc. Analysis of nucleic acid sequences
EP4574974A3 (en) 2014-06-26 2025-10-08 10x Genomics, Inc. Methods of analyzing nucleic acids from individual cells or cell populations
CN110478495A (zh) 2014-06-30 2019-11-22 塔弗达治疗有限公司 靶向缀合物及其颗粒和制剂
WO2016025480A1 (en) * 2014-08-11 2016-02-18 The General Hospital Corporation Cyclooctenes for bioorthogonol reactions
CN104356110B (zh) * 2014-11-19 2018-01-23 西北大学 一种硫诱导3,6‑芳香杂环不对称取代‑1,2,4,5‑四嗪化合物及其合成方法
IL300408B2 (en) 2015-01-20 2025-11-01 Cytomx Therapeutics Inc Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof
CA2978340C (en) 2015-03-27 2024-05-28 Regeneron Pharmaceuticals, Inc. Maytansinoid derivatives, conjugates thereof, and methods of use
US20160331852A1 (en) * 2015-05-11 2016-11-17 Memorial Sloan Kettering Cancer Center Radioligands for pretargeted pet imaging and methods of their therapeutic use
WO2017007755A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
HUE057041T2 (hu) 2015-07-06 2022-04-28 Alkermes Inc Hiszton deacetiláz hetero-halogén gátlói
CN108135857A (zh) * 2015-09-10 2018-06-08 沙思奇公司 生物正交组合物
GB201516480D0 (en) 2015-09-17 2015-11-04 Univ Edinburgh Tetrazine as a trigger to release caged cargo
EP3153155B1 (en) * 2015-10-08 2021-03-03 President and Fellows of Harvard College Refillable drug delivery devices and methods of use thereof
CN108473538B (zh) 2015-10-28 2022-01-28 塔弗达治疗有限公司 Sstr靶向缀合物及其颗粒和制剂
US10875840B2 (en) * 2015-12-15 2020-12-29 University Of Delaware Methods for inducing bioorthogonal reactivity
MX390630B (es) 2016-01-25 2025-03-21 Regeneron Pharma Derivados de maitansinoide, conjugados de los mismos y metodos de uso.
WO2017156164A1 (en) 2016-03-09 2017-09-14 Board Of Regents, The University Of Texas System 20-hete receptor (gpr75) antagonists and methods of use
BR112018070537B1 (pt) 2016-04-06 2022-11-01 Sumitomo Chemical Company, Limited Composto heterocíclico, composição compreendendo o mesmo e seus usos
US11617799B2 (en) * 2016-06-27 2023-04-04 Tagworks Pharmaceuticals B.V. Cleavable tetrazine used in bio-orthogonal drug activation
HRP20220223T1 (hr) 2017-01-11 2022-04-29 Alkermes, Inc. Biciklički inhibitori histon deacetilaze
EP3385779A1 (en) * 2017-04-05 2018-10-10 Koninklijke Philips N.V. Multi-view display device and method
AU2018250312C1 (en) 2017-04-07 2024-08-22 Tambo, Inc. Bioorthogonal compositions
CN107281204A (zh) * 2017-05-04 2017-10-24 北京大学 一种非对称的1,2,4,5‑四嗪分子的应用
US11560384B2 (en) 2017-05-04 2023-01-24 University Of Utah Research Foundation Benzonorbornadiene derivatives and reactions thereof
EP3651741A4 (en) * 2017-07-14 2021-04-21 The Penn State Research Foundation COMPOSITIONS AND METHODS OF TARGETED DELIVERY OF A THERAPEUTIC AND / OR DIAGNOSTIC SPECIES
US11225475B2 (en) 2017-08-07 2022-01-18 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase
US10837047B2 (en) * 2017-10-04 2020-11-17 10X Genomics, Inc. Compositions, methods, and systems for bead formation using improved polymers
EP3691703A1 (en) 2017-10-04 2020-08-12 10X Genomics, Inc. Compositions, methods, and systems for bead formation using improved polymers
WO2019084323A1 (en) 2017-10-25 2019-05-02 Georgia State University Research Foundation, Inc. CHEMICAL RELEASE SYSTEM DELIVERED BY ENRICHMENT
EP3625361A1 (en) 2017-11-15 2020-03-25 10X Genomics, Inc. Functionalized gel beads
WO2019099908A1 (en) 2017-11-17 2019-05-23 10X Genomics, Inc. Methods and systems for associating physical and genetic properties of biological particles
CN111989324A (zh) * 2018-04-11 2020-11-24 墨尔本大学 靶向化合物及其生产方法
AU2019262521B2 (en) * 2018-05-04 2024-04-18 Tagworks Pharmaceuticals B.V. Compounds comprising a linker for increasing transcyclooctene stability
CA3099419A1 (en) 2018-05-04 2019-11-07 Tagworks Pharmaceuticals B.V. Tetrazines for high click conjugation yield in vivo and high click release yield
EP3787612A4 (en) 2018-05-04 2021-11-17 Remedy Plan, Inc. CANCER TREATMENTS AGAINST CANCER STEM CELLS
US11584749B2 (en) 2018-05-31 2023-02-21 Spark Biopharma, Inc. Phosphor-tetrazine compound and use thereof
KR102011772B1 (ko) * 2018-05-31 2019-08-19 (주)스파크바이오파마 신규한 형광체-테트라진 화합물 및 이의 용도
JP7337174B2 (ja) 2018-09-18 2023-09-01 ニカング セラピューティクス, インコーポレイテッド Srcホモロジー-2ホスファターゼ阻害剤としての三置換ヘテロアリール誘導体
WO2020077140A1 (en) * 2018-10-10 2020-04-16 Tambo, Inc. Processes for preparing functionalized cyclooctenes
JP2022512124A (ja) 2018-12-06 2022-02-02 シートムエックス セラピューティクス,インコーポレイテッド マトリックスメタロプロテアーゼ切断可能なおよびセリンまたはシステインプロテアーゼ切断可能な基質ならびにそれらの使用方法
WO2020123882A1 (en) 2018-12-12 2020-06-18 The General Hospital Corporation Prodrugs with a tridentate self-immolative linker
CN112010817A (zh) * 2019-05-31 2020-12-01 四川大学华西医院 一种制备四嗪类化合物的方法及其应用
IL289094A (en) 2019-06-17 2022-02-01 Tagworks Pharmaceuticals B V Tetrazines for increasing the speed and yield of the "click release" reaction
CA3143924C (en) 2019-06-17 2025-06-03 Tagworks Pharmaceuticals B.V. Agents that allow in vivo cleavage of markers linked to biomolecules
WO2020256546A1 (en) 2019-06-17 2020-12-24 Tagworks Pharmaceuticals B.V. Compounds for fast and efficient click release
PH12022551081A1 (en) 2019-11-06 2024-06-19 Remedy Plan Inc Cancer treatments targeting cancer stem cells
CN113321698B (zh) * 2020-02-28 2022-08-23 国家纳米科学中心 一种单甲基澳瑞他汀e前药及其制备方法和应用
CN113321702B (zh) * 2020-02-28 2022-08-05 国家纳米科学中心 一种单甲基澳瑞他汀f甲酯前药及其制备方法和应用
CN113354657B (zh) * 2020-03-05 2022-10-21 国家纳米科学中心 一种Mytoxin A前药及其制备方法和应用
EP3909944A1 (en) * 2020-05-14 2021-11-17 Rigshospitalet Nuclide labelled h-tetrazines and use thereof for pet and spect pretargeted imaging and radionuclide therapy
JP2023537066A (ja) * 2020-08-07 2023-08-30 タンボ・インコーポレイテッド トランス-シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用
WO2022047054A2 (en) 2020-08-27 2022-03-03 The Texas A&M University System Inhibitors of sars cov-2 infection and uses thereof
WO2022072949A2 (en) * 2020-10-02 2022-04-07 The General Hospital Corporation Bioorthogonal linkers and reactions
WO2022197877A1 (en) 2021-03-19 2022-09-22 Genentech, Inc. Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
WO2023028168A2 (en) * 2021-08-25 2023-03-02 R.P. Scherer Technologies, Llc Methods of using antibody-drug-conjugates
WO2023081809A1 (en) * 2021-11-05 2023-05-11 Tambo, Inc. Trans-cyclooctene-modified bispecific antibodies
DK4186529T3 (da) * 2021-11-25 2025-08-25 Veraxa Biotech Gmbh Forbedrede antistof-payload-konjugater (apc) fremstillet ved stedspecifik konjugering ved hjælp af genetisk kodeudvidelse
EP4372000B1 (en) 2022-02-15 2026-06-17 Tagworks Pharmaceuticals B.V. Masked il12 protein
CN114652857B (zh) * 2022-03-31 2023-10-20 成都大学 一种用于修复内皮糖萼受损的靶向药物递送系统及其制备方法
CN115974892B (zh) * 2022-12-27 2023-09-08 四川大学华西医院 三氮唑四嗪类化合物及其制备方法、应用
KR20250141267A (ko) * 2023-02-15 2025-09-26 태그웍스 파마슈티컬스 비.브이. 개선된 특성을 가지는 테트라진
CN116370650B (zh) * 2023-04-14 2024-03-22 四川大学华西医院 基于四嗪连接子的多肽药物偶联物及其制备方法、应用
CN116675664B (zh) * 2023-04-21 2025-06-24 苏州大学 一种生物正交断键反应体系及前药与应用
WO2025043219A1 (en) * 2023-08-24 2025-02-27 The Regents Of The University Of California Methods for uncaging tetrazines
WO2025166249A1 (en) * 2024-01-31 2025-08-07 Oregon State University Tetrazine amino acids and methods for their production and use
CN117700394B (zh) * 2024-02-06 2024-05-28 南京大学 一类可与非张力烯基硼酸快速环加成反应的四嗪类化合物及其生物医药应用
WO2025174248A1 (en) * 2024-02-16 2025-08-21 Tagworks Pharmaceuticals B.V. Trans-cyclooctenes with "or gate" release
CN117752824A (zh) * 2024-02-21 2024-03-26 中国医学科学院医学实验动物研究所 预靶向肿瘤免疫探针、生物正交制剂、试剂盒及应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826964A (en) 1982-07-20 1989-05-02 Sri International Bridged oxygen analogs of daunorubcin and doxorubicin
US4486414A (en) 1983-03-21 1984-12-04 Arizona Board Of Reagents Dolastatins A and B cell growth inhibitory substances
US4486444A (en) 1983-06-20 1984-12-04 Merck & Co., Inc. (Hydroxybenzoyl)thiophenesulfonamide and acyl derivatives thereof for the topical treatment of elevated intraocular pressure
US4879278A (en) 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
US4986988A (en) 1989-05-18 1991-01-22 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
US5138036A (en) 1989-11-13 1992-08-11 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14
US5198560A (en) 1990-04-27 1993-03-30 Bristol-Myers Squibb Company Cytotoxic bicyclo[7.3.1]tridec-4-ene-2,6-diyne compounds and process for the preparation thereof
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US6034065A (en) 1992-12-03 2000-03-07 Arizona Board Of Regents Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
US5410024A (en) 1993-01-21 1995-04-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5504191A (en) 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5521284A (en) 1994-08-01 1996-05-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides and esters
US5530097A (en) 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
EP0904066A4 (en) 1996-05-03 2002-04-24 Roger S Cubicciotti DRUG COMPOSITIONS AND METHOD FOR ADMINISTERING DRUGS USING SYNTHETIC RECEPTORS
CA2282504A1 (en) 1997-02-25 1998-08-27 Jun-Ping Xu Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
US8236949B2 (en) * 2007-07-17 2012-08-07 University Of Delaware Tetrazine-based bio-orthogonal coupling reagents and methods
WO2009109998A1 (en) 2008-03-03 2009-09-11 Lupin Limited Novel protein tyrosine phosphatase - ib inhibitors
CN102271712B (zh) 2008-10-31 2015-11-25 通用医疗公司 用于将物质递送至生物靶标的组合物和方法
GB0906379D0 (en) * 2009-04-14 2009-05-20 Kencryst Ltd Reduced sodium salt
WO2010119389A2 (en) * 2009-04-16 2010-10-21 Koninklijke Philips Electronics N.V. Pretargeting kit, method and agents used therein
US20120039803A1 (en) 2009-04-16 2012-02-16 Koninklijke Philips Electronics N.V. Pretargeting kit, method and agents used therein
CN103221398B (zh) 2010-07-23 2016-03-23 特拉华大学 用于快速构建放射性核素标记探针的四嗪-反式环辛烯连接反应
WO2012049624A1 (en) * 2010-10-14 2012-04-19 Koninklijke Philips Electronics N.V. Pretargeting kit, method and agents used therein
JP5992435B2 (ja) * 2010-12-21 2016-09-14 コーニンクレッカ フィリップス エヌ ヴェKoninklijke Philips N.V. 循環からの生体分子の除去剤
EP2522369A1 (en) * 2011-05-09 2012-11-14 Koninklijke Philips Electronics N.V. Pretargeting kit, method and agents used therein
EP2709666B1 (en) 2011-05-16 2021-07-14 Koninklijke Philips N.V. Bio-orthogonal drug activation
WO2014065860A1 (en) 2012-10-24 2014-05-01 The General Hospital Corporation Functionalized 1,2,4,5-tetrazine compounds for use in bioorthogonal coupling reactions
US20150297741A1 (en) 2012-11-22 2015-10-22 Tagworks Pharmaceuticals B.V. Bio-orthogonal drug activation
US10927139B2 (en) 2012-11-22 2021-02-23 Tagworks Pharmaceuticals B.V. Chemically cleavable group
WO2016025480A1 (en) 2014-08-11 2016-02-18 The General Hospital Corporation Cyclooctenes for bioorthogonol reactions
US11617799B2 (en) * 2016-06-27 2023-04-04 Tagworks Pharmaceuticals B.V. Cleavable tetrazine used in bio-orthogonal drug activation
AU2019262521B2 (en) * 2018-05-04 2024-04-18 Tagworks Pharmaceuticals B.V. Compounds comprising a linker for increasing transcyclooctene stability
CA3099419A1 (en) * 2018-05-04 2019-11-07 Tagworks Pharmaceuticals B.V. Tetrazines for high click conjugation yield in vivo and high click release yield
WO2020256546A1 (en) * 2019-06-17 2020-12-24 Tagworks Pharmaceuticals B.V. Compounds for fast and efficient click release
CA3143924C (en) * 2019-06-17 2025-06-03 Tagworks Pharmaceuticals B.V. Agents that allow in vivo cleavage of markers linked to biomolecules
IL289094A (en) * 2019-06-17 2022-02-01 Tagworks Pharmaceuticals B V Tetrazines for increasing the speed and yield of the "click release" reaction

Similar Documents

Publication Publication Date Title
IL272656B (en) Analogues of oligonucleotides containing inter-subunit bonds and/or terminal groups, preparations containing them and their uses
JP2012520430A5 (enExample)
EP4357355A3 (en) Virus purification
HK1215595A1 (zh) 白細胞介素-10藥物組合物和使用方法
JP2012012401A5 (enExample)
JP2014009322A5 (enExample)
WO2014145932A3 (en) Specific multivalent virus-like particle vaccines and uses thereof
JP2013001794A5 (enExample)
JP2010529364A5 (enExample)
JP2013501834A5 (enExample)
WO2015010791A3 (en) Novel antibodies for the diagnosis and treatment of rheumatoid arthritis
AR100745A1 (es) Nanopartículas de quitosano cargadas con antígeno para inmunoterapia
JP2016509026A5 (enExample)
EP4226936A3 (en) Non-neuroinvasive viruses and uses thereof
JP2013522131A5 (enExample)
JP2015030781A5 (enExample)
WO2015066135A3 (en) Metal ligand-containing prepolymers, methods of synthesis, and compositions thereof
JP2011125841A5 (enExample)
WO2016027160A3 (en) Nasal composition comprising mixture of hyaluronic acids and saline solution
RU2012157586A (ru) Фиточай
JP2014520972A5 (enExample)
JP2012130323A5 (enExample)
JP2013160948A5 (enExample)
CN302151609S (zh) 酒瓶(丰谷窖藏)
RU2012133422A (ru) Полимерная композиция